Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working Group.
acute coronary syndrome
consensus
guidelines
haemophilia
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
16
09
2022
received:
01
07
2022
accepted:
20
09
2022
pubmed:
23
10
2022
medline:
25
1
2023
entrez:
22
10
2022
Statut:
ppublish
Résumé
As people with haemophilia (PWH) receive better treatment and live longer they are more likely to encounter cardiovascular disease (CVD) and other comorbidities. ESC guidelines for the acute management of patients presenting with acute coronary syndrome (ACS) are based on the non-haemophilia population. To review the guidelines and propose relevant adaptations for PWHA without inhibitors who are treated with prophylaxis and present with ACS. As part of the ADVANCE Group, 20 European haemophilia experts used a modified Delphi approach to develop and gain consensus on proposed adaptations of the ESC guidelines for PWHA without inhibitors. Of the 32 Class I recommendations across both guidelines, adaptions were considered necessary and proposed for 15. The adaptions highlight the need to provide sufficient FVIII trough levels at the time of antithrombotic treatment in people with haemophilia A (HA) without inhibitors. Patients receiving emicizumab prophylaxis and requiring oral anticoagulation therapy or combined single antiplatelet plus oral anticoagulation therapy will require additional FVIII replacement therapy. In the absence of high-quality clinical evidence, the combined expert opinion used to develop these adaptions to the current ESC guidelines may help to guide clinicians in their treatment decisions when a PWHA presents with ACS.
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-32Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815-825.
Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost. 2006;4:510-516.
Guillet B, Cayla G, Lebreton A, et al. Long-term antithrombotic treatments prescribed for cardiovascular diseases in patients with hemophilia: results from the French Registry. Thromb Haemost. 2021;121:287-296.
Hay CRM, Nissen F, Pipe SW. Mortality in congenital hemophilia A - a systematic literature review. J Thromb Haemost. 2021;19(suppl 1):6-20.
Skjefstad K, Solberg O, Glosli H, von der Lippe C, Feragen KB. Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986-2018. Eur J Haematol. 2020;105:608-615.
Zimmermann R, Staritz P, Huth-Kuhne A. Challenges in treating elderly patients with haemophilia: a focus on cardiology. Thromb Res. 2014;134(suppl 1):S48-S52.
Holme PA, Combescure C, Tait RC, et al. Hypertension, haematuria, and renal functioning in haemophilia - a cross-sectional study in Europe. Haemophilia. 2016;22:248-255.
Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia: contemporary concerns. Semin Hematol. 2016;53:35-39.
Angelini D, Sood SL. Managing older patients with hemophilia. Hematology Am Soc Hematol Educ Program. 2015;2015:41-47.
Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis. 2011;22:402-406.
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.
Khleif AA, Rodriguez N, Brown D, Escobar MA. Multiple comorbid conditions among middle-aged and elderly hemophilia patients: prevalence estimates and implications for future care. J Aging Res. 2011;2011:985703.
Miesbach WA, Di Minno G, Santagostino E, et al. Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) prophylaxis in patients with severe hemophilia A and comorbidities: a post hoc analysis of PROTECT VIII data. Blood. 2019;134(supplement 1):1117. https://doi.org/10.1182/blood-2019-128486
Pocoski J, Ma A, Kessler CM, Boklage S, Humphries TJ. Cardiovascular comorbidities are increased in U.S. patients with haemophilia A: a retrospective database analysis. Haemophilia. 2014;20:472-478.
Badescu MC, Ciocoiu M, Rezus E, et al. Current therapeutic approach to acute myocardial infarction in patients with congenital hemophilia. Life (Basel). 2021;11:1072.
Biere-Rafi S, Tuinenburg A, Haak BW, et al. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost. 2012;10:30-37.
Zwiers M, Lefrandt JD, Mulder DJ, et al. Coronary artery calcification score and carotid intima-media thickness in patients with hemophilia. J Thromb Haemost. 2012;10:23-29.
Ibanez B, James S, Agewall S, et al. ESC Guidelines for the management of acute MI in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119-177.
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289-1367.
Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a Delphi group opinion technic. N Engl J Med. 1973;288:1272-1275.
Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Evaluation. 2007;12:1-8.
Hemlibra 150 mg/mL Solution for Injection - Summary of Product Characteristics. Accessed June 15, 2022. https://www.medicines.org.uk/emc/product/9043/smpc
Staritz P, de Moerloose P, Schutgens R, Dolan G, ADVANCE Working Group. Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group. Haemophilia. 2013;19:833-840.
Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood. 2016;128:178-184.
Boehnel C, Rickli H, Graf L, Maeder MT. Coronary angiography with or without percutaneous coronary intervention in patients with hemophilia - systematic review. Catheter Cardiovasc Interv. 2018:92:1-15.
Ferraris VA, Boral LI, Cohen AJ, Smyth SS, White GC II. Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev. 2015;23:53-68.
Jabbar AY, Baydoun H, Janbain M, Ferdinand KC. Current concepts in the management of stable ischemic heart disease and acute coronary syndrome in patients with hemophilia. Ann Transl Med. 2018;6:299.
Mannucci PM, Mauser-Bunschoten EP. Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia. 2010;16(suppl 3):58-66.
Claassens DMF, Bergmeijer TO, Vos GJA, et al. Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype: a POPular genetics sub analysis. Circ Cardiovasc Interv. 2021;14:e009434.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
Guan W, Lu H, Yang K. Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: a systematic review and meta-analysis (2007-2017). Medicine (Baltimore). 2018;97:e12978.
Shoji S, Sawano M, Sandhu AT, et al. Ischemic and bleeding events among patients with acute coronary syndrome associated with low-dose prasugrel vs standard-dose clopidogrel treatment. JAMA Netw Open. 2020;3(4):e202004.
Murray NP, Muñoz L, Minzer S, Lopez MA. Management of thrombosis risk in a carrier of hemophilia A with low factor viii levels with atrial fibrillation: a clinical case and literature review. Case Rep Hematol 2018;2018:2615-2838.
Ay C, Feistritzer C, Rettl J, et al. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Sci Rep. 2021;11:12967.
Van Der Valk P, Makris M, Fischer K, et al. Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Adv. 2022;6:902-908.
Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: the ups and downs of treatment. Blood Rev. 2021;50:100852.
Misgav M, Brutman-Barazani T, Budnik I, et al. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real-world data. Haemophilia. 2021;27:253-260.
Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia a patients treated with emicizumab. J Clin Med. 2021;10:4303.
Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv. 2020;4:2111-2118.
Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia 2022;28(suppl 4):103-110.